Please assess the completion status of the following clinical trial:

Trial Title: A Study of MRG003 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to sign the ICF and follow the requirements specified in the protocol.~* Age: ≥18 years and ≤75 years, both genders~* Expected survival time≥12 weeks~* Phase Ia: Patients with histologically and cytologically confirmed advanced or metastatic solid tumor~* Phase Ib: Patients with histologically and cytologically confirmed EGFR-positive advanced or metastatic colorectal cancer, squamous cell carcinoma of head and neck, and nasopharyngeal carcinoma~* Subjects must have measurable lesions according to the response Evaluation Criteria In Solid Tumors（RECIST v1.1）~* ECOG performance score 0 or 1~* Acceptable liver, renal, and hematologic function~* Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment~Exclusion Criteria:~* History of hypersensitivity to any component of the investigational product~* Presence of central nervous system metastasis~* Prior history of other primary malignancies~* Known history of clinically significant hepatic diseases~* Evidence of active infection of human immunodeficiency virus (HIV)~* History of ophthalmic abnormalities~* Any severe or uncontrolled systemic disease judged by the investigator~* Patients with poorly controlled heart diseases~* Received radiotherapy, chemotherapy, biotherapy, immunotherapy or other anti-tumor drugs within 4 weeks prior to the first dose of study treatment~* Major surgery or surgical therapy for any cause within 4 weeks prior to the first dose of investigational drug~* Planned surgery or surgery is the best interest of patients as determined by investigator~* History of severe skin disease requiring interruption of previous EGFR targeted therapy; or chronic skin disease requiring oral or intravenous therapy~* Active concomitant diseases that might increase risks of toxicity~* Pregnancy, or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRG003 (Type: EXPERIMENTAL): Phase Ia: MRG003 will be administrated by an IV infusion of escalating doses (0.1, 0.3, 0.6, 1.0, 2.0, 2.5, 3.0 mg/kg) on Day 1 of every 3 weeks (Q3W); Phase Ib: MRG003 will be administrated by an IV infusion of MTD/RP2D.

Based on this trial design, predict the completion outcome and termination type (if applicable).